Revenue
2018
2019
2020
2021
2022
2023
2024
2025
CYTOKINETICS INC (CYTK)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88.0M | $18.5M | $7.5M | $94.6M | $70.4M | $55.8M | $26.9M | $31.5M | $13.4M | $106.4M | $28.7M | $46.9M | $30.6M | $7.6M | $4.0M | $2.6M | $81.5M | — | — | — | — | — | — | — | — | — | — |
| Research & development | $416.0M | $339.4M | $330.1M | $240.8M | $159.9M | $97.0M | $86.1M | $89.1M | $90.3M | $59.9M | $46.4M | $44.4M | $49.5M | $35.6M | $37.2M | $38.0M | $39.8M | — | — | — | — | — | — | — | — | — | — |
| Operating expenses | $700.3M | $554.7M | $503.7M | $418.8M | $256.7M | $149.8M | $125.7M | $120.4M | $126.8M | $87.7M | $66.1M | $61.7M | $64.5M | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | −$612.3M | −$536.2M | −$496.2M | −$324.2M | −$186.3M | −$93.9M | −$98.9M | −$88.9M | −$113.4M | $18.7M | −$37.4M | −$14.8M | −$33.9M | −$40.5M | −$48.0M | −$49.6M | $26.1M | — | — | — | — | — | — | — | — | — | — |
| EBITDAderived | −$602.1M | −$526.7M | −$484.3M | −$318.4M | −$184.0M | −$92.1M | −$97.6M | −$87.7M | −$111.5M | $19.4M | −$36.8M | −$14.3M | −$33.5M | −$39.9M | −$46.7M | −$47.7M | $28.1M | — | — | — | — | — | — | — | — | — | — |
| Net income | −$785.0M | −$589.5M | −$526.2M | −$389.0M | −$215.3M | −$127.3M | −$121.7M | −$106.3M | −$127.8M | $16.5M | −$37.5M | −$14.6M | −$33.7M | −$40.4M | −$47.9M | −$49.3M | $24.5M | −$56.4M | −$48.9M | −$57.1M | −$42.3M | −$37.2M | −$32.7M | −$23.1M | −$15.9M | −$13.1M | −$7.3M |
| Basic EPSper diluted share | -$6.54 | -$5.26 | -$5.45 | -$4.33 | -$2.80 | -$1.97 | -$2.11 | -$1.95 | -$2.59 | $0.41 | -$0.97 | -$0.41 | -$1.24 | -$2.30 | -$0.72 | -$0.77 | $0.43 | — | — | — | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | -$6.54 | -$5.26 | -$5.45 | -$4.33 | -$2.80 | -$1.97 | -$2.11 | -$1.95 | -$2.59 | $0.39 | -$0.97 | -$0.41 | -$1.24 | -$2.30 | -$0.72 | -$0.77 | $0.42 | — | — | — | — | — | — | — | — | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 29, 2026Form 4 · 10b5-1 | Lee SungEVP, Chief Financial Officer | SellCommon Stock | 3.1K | $85.00 | $266.4K | 63.2K |
| Jun 24, 2026Form 4 · 10b5-1 | Lee SungEVP, Chief Financial Officer | SellCommon Stock | 38.7K | $82.30 | $3.19M | 63.2K |
| Jun 23, 2026Form 4 · 10b5-1 | Malik Fady IbrahamEVP Research & Development | SellCommon Stock | 3.5K | $79.51 | $278.3K | 153.9K |
| Jun 15, 2026Form 4 · 10b5-1 | Blum Robert IPresident & CEO | SellCommon Stock | 7.5K | $70.46 | $528.5K | 385.3K |
| Jun 9, 2026Form 4 · 10b5-1 | Malik Fady IbrahamEVP Research & Development | SellCommon Stock | 3.5K | $67.98 | $237.9K | 153.9K |